Skip to content
Aussie8 – Lifestyle
Author:
Stelexis BioSciences, Inc.
Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
June 2, 2026